ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

LPCN Lipocine Inc

4,7983
0,2483 (5,46%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Lipocine Inc LPCN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,2483 5,46% 4,7983 06:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,52 4,38 4,8099 4,7977 4,55
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
11.4.202413:00PRNUSLipocine Announces Positive LPCN 2401 Clinical Results..
28.3.202413:00PRNUSLipocine Announces Positive Week 52 Results from LPCN 1148..
25.3.202413:00PRNUSLipocine Announces First Cohort Dosed in Pivotal Study of..
07.3.202423:31EDGAR2Form 8-K - Current report
07.3.202414:00PRNUSLipocine Announces Financial Results for the Full Year Ended..
07.3.202412:08EDGAR2Form 8-K - Current report
07.3.202412:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06.3.202414:00PRNUSLipocine to Present at 36th Annual Roth Conference
06.3.202412:01EDGAR2Form 8-K - Current report
12.2.202422:10EDGAR2Form 8-K - Current report
06.2.202414:00PRNUSLipocine Announces Confirmation of Dosing Regimen for..
02.2.202414:00PRNUSLipocine Announces Continued Commercialization of TLANDO®..
18.1.202414:20EDGAR2Form 8-K - Current report
18.1.202414:00PRNUSLipocine and Verity Pharma Enter into License Agreement for..
19.12.202316:00EDGAR2Form 8-K - Current report
19.12.202314:00PRNUSLipocine to Present at Biotech Showcase 2024
22.11.202322:15EDGAR2Form S-3 - Registration statement under Securities Act of..
13.11.202320:45EDGAR2Form 8-K - Current report
13.11.202320:45PRNUSLipocine Releases Late Breaking Presentation on LPCN 1148..
08.11.202319:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202315:50EDGAR2Form 8-K - Current report
08.11.202314:00PRNUSLipocine Announces Financial Results for the Third Quarter..
01.11.202314:31EDGAR2Form 8-K - Current report
01.11.202313:00PRNUSLipocine to Present Clinical Data on LPCN 1148 at The Liver..
26.10.202315:35EDGAR2Form 8-K - Current report
26.10.202314:00PRNUSLipocine Completes Successful Meeting with FDA on LPCN 1154..
24.10.202301:00PRNUSLipocine to Present at the H.C. Wainwright Annual NASH..
06.10.202322:05EDGAR2Form 8-K - Current report
19.9.202322:10EDGAR2Form 8-K - Current report
19.9.202322:05PRNUSLipocine to Present at the Cantor Fitzgerald Global..
10.8.202314:35EDGAR2Form 8-K - Current report
10.8.202314:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202314:00PRNUSLipocine Announces Financial Results for the Second Quarter..
27.7.202312:45EDGAR2Form 8-K - Current report
27.7.202312:30PRNUSLPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients..
14.6.202314:00PRNUSLipocine to Present at H.C. Wainwright Annual..
07.6.202314:00PRNUSLipocine to Present LPCN 1148 and LPCN 1144 at the EASL..
16.5.202313:00PRNUSPositive Topline Clinical Results Support Streamlined..
11.5.202312:00PRNUSLipocine Announces Financial Results for the First Quarter..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock